

# Supplementary Materials

**Table S1..** Accuracy and precision of Trastuzumab measured in plasma with mAbXmise kit. Results obtained with biosimilar of Trastuzumab (Ontruzant®) using two distinct peptides. <sup>a</sup>Precision is expressed as coefficient of variation (%).

Trastuzumab DTYIHWVR	Nominal concentration (µg/mL)	Mean calculated concentration (µg/mL)	Precision <sup>a</sup> (%, n=6))	Accuracy (%) n=6
Ontruzant®				
	6	6.3	8.9	104.7
	15	16.0	8.6	106.6
	75	79.7	4.0	106.3
Trastuzumab FTISADTSK	Nominal concentration (µg/mL)	Mean calculated concentration (µg/mL)	Precision <sup>a</sup> (%, n=6))	Accuracy (%) n=6
Ontruzant®				
	6	5.9	2.1	99.8
	15	16.3	2.2	108.7
	75	82.8	2.7	110.4

**Table S2.** Intra-assay accuracy and precision of OTDM1 monoclonal antibodies measured in plasma spiked at 250 µg/mL and then diluted by 5in PBS 1X or plasma, with mAbXmise kit. Results obtained with originators drugs.  
<sup>a</sup> Precision is expressed as coefficient of variation.

Within-run				
	Nominal concentration (µg/mL)	Mean Calculated concentration (µg/mL)	Intra-day precision <sup>a</sup> (%, n = 6)	Intra-day accuracy (%, n = 6)
<b>Bevacizumab</b>				
<b>FTFSLDTSK</b>				
PBS	250	253.9	1.5	101.6
Plasma	250	257.8	1.7	103.1
<b>Cetuximab</b>				
<b>YASESGIPSR</b>				
PBS	250	259.8	2.8	103.9
Plasma	250	256.3	2.3	102.5
<b>Ipilimumab</b>				
<b>GLEWVTFISYDGNNK</b>				
PBS	250	284.9	9.32	114.0
Plasma	250	234.2	8.91	93.7
<b>Nivolumab</b>				
<b>ASGITFSNSGMHWVR</b>				
PBS	250	230.9	2.9	92.4
Plasma	250	249.2	5.9	99.7
<b>Pembrolizumab</b>				
<b>DLPLTFGGGTK</b>				
PBS	250	257.8	1.8	103.1
Plasma	250	262.3	1.4	104.9
<b>Rituximab</b>				
<b>FSGSGSGTSYSLTISR</b>				
PBS	250	267.0	3.1	106.8

Plasma	250	263.8	6.4	105.5
<b>Trastuzumab</b>				
<b>DTYIHWVR</b>				
PBS	250	238.6	1.8	95.4
Plasma	250	259.8	4.6	103.9
<b>Trastuzumab</b>				
<b>FTISADTSK</b>				
PBS	250	242.6	2.0	97.0
Plasma	250	252.3	1.8	100.9